SERUM PROTEINS AND TUMOR MARKERS IN RENAL ARTERIAL AND VENOUS BLOOD IN PATIENTS WITH RENAL CANCER

摘要

In order to investigate an in vivo production of some serum proteins which are most commonly elevated in renal cancer patients and tumor markers in renal cancer tissue, their concentrations in renal arterial and venous blood samples have been determined in 11 patients with renal cancer. In other 2 groups, one consisting of 13 renal cancer patients without metastasis and another 13 renal cancer patients with metastasis, pre- and post-operative changes of concentration of 36 serum proteins in peripheral blood have been studied as well. The 36 serum proteins were quantitatively determined by a micro-single radial immune diffusion method described by Migita and 5 tumor markers, beta-human chorionic gonadotropin (β-HCG), alpha-fetoprotein (AFP), ferritin, carcinoembryonic antigen (CEA) and beta-2 micro globulin (BMG), were determined using commercially available radioimmunoassay kits, From the data obtained from the 11 patients, it was not possible to assure the production of any serum protein in renal cancerous tissue, A large variety of serum proteins showing a decrease of the concentration in renal venous blood had a relatively close relationship to patients with a large tumor lesion, Although a sporadic increase of several serum proteins in the venous blood was observed, it was not limited to a specified patient. Productions ofβ-HCG, BMG and ferritin in renal cancerous tissue were strongly suggested ml, 1 and 5 patients, respectively, In a group of the 13 patients without metastasis, abnormal levels of Alb, α1AT, α1AG, Hp, C 9 and Hx returned to a normal range after nephrectomy, and these post-operativeα1AT, α1AG, Hp and Hx levels showed a significant difference as compared with P8st-operative levels of those proteins in the 13 patients with metastasis. These results suggested that post-cperative changes of the 4 serum proteins would be a useful parameter for the occurrence of a deteriorating event in the subsequent course, e.g., tumor recurrence or metastasis development.